The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL
Enrollment

2,165

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
DRUG

Saxagliptin

oral, 5 mg once a day (Q.D.)

Trial Locations (37)

Unknown

Research Site, Baotou

Research Site, Beijing

Research Site, Benxi

Research Site, Changchun

Research Site, Chengdu

Research Site, Chongqing

Research Site, Dalian

Research Site, Dongguan

Research Site, Foshan

Research Site, Fuzhou

Research Site, Guangzhou

Research Site, Guiyang

Research Site, Haikou

Research Site, Hangzhou

Research Site, Hhht

Research Site, Hubei

Research Site, Jimo

Research Site, Jinan

Research Site, Kunming

Research Site, Linyi

Research Site, Nanjing

Research Site, Nantong

Research Site, Qingdao

Research Site, Shanghai

Research Site, Shantou

Research Site, Shenyang

Research Site, Shiyan

Research Site, Suzhou

Research Site, Taiyuan

Research Site, Tianjin

Research Site, Ürümqi

Research Site, Wenzhou

Research Site, Wuhan

Research Site, Wuxi

Research Site, Xi'an

Research Site, Zhanjiang

Research Site, Zhengzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY